Back to Stocks

NUWE

Nuwellis, Inc.
2 filings tracked
healthcaremedical devicesMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Nuwellis is demonstrating a powerful commercial inflection point, highlighted by a 26.2% year-over-year increase in net sales for the first quarter of 2026.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of margin expansion, Nuwellis remains in a precarious financial position with a widening net loss of $4.54 million for the quarter.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every NUWE filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a stark contrast between operational progress and financial instability. On one hand, the Aquadex system is seeing unprecedented demand and the company has successfully optimized its cost of goods sold. On the other hand, the company is fighting a battle against a depleting cash runway and a history of substantial accumulated deficits totaling $320.9 million. The integration of Rendiatech and the focus on the U.S. market are the primary catalysts for future growth, but these initiatives require capital that the company does not currently possess. Investors are left weighing the impressive 70% gross margins against a 'going concern' warning and the immediate need for additional financing. The ultimate success of the turnaround depends on whether the current sales momentum can be converted into cash flow before the company exhausts its remaining liquidity.

Selected Quarter

Core Takeaway

Nuwellis is proving its product-market fit with surging console sales, but it is running out of money to fund the growth.

Investor Lens

The trade-off is between impressive commercial momentum and the high probability of further shareholder dilution.

Watch Next

Announcement of new financing or ATM sales to extend the runway beyond Q2 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.17Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 15

Net loss widened to $4.54 million due to increased operating expenses.

earnings miss
70%
bullishMay 15

Gross margin increased significantly to 70.1% via manufacturing optimization.

margin expansion
90%
neutralMay 15

Raised approximately $5 million through a PIPE and warrant inducement transaction.

capital raise
60%
bullishMay 15

Acquired Rendiatech to add automated kidney function monitoring technology.

acquisition
50%
bearishMay 15

Net loss widened to $4.54 million due to increased operating expenses.

earnings miss
70%
bullishMay 15

Gross margin increased significantly to 70.1% via manufacturing optimization.

margin expansion
90%
neutralMay 15

Raised approximately $5 million through a PIPE and warrant inducement transaction.

capital raise
60%
bullishMay 15

Acquired Rendiatech to add automated kidney function monitoring technology.

acquisition
50%

Filing History

10-QMay 15, 2026
Expand Sequence

The Q1 2026 filing presents a stark contrast between operational progress and financial instability. On one hand, the Aquadex system is seeing unprecedented demand and the company has successfully optimized its cost of goods sold. On the other hand, the company is fighting a battle against a depleting cash runway and a history of substantial accumulated deficits totaling $320.9 million. The integration of Rendiatech and the focus on the U.S. market are the primary catalysts for future growth, but these initiatives require capital that the company does not currently possess. Investors are left weighing the impressive 70% gross margins against a 'going concern' warning and the immediate need for additional financing. The ultimate success of the turnaround depends on whether the current sales momentum can be converted into cash flow before the company exhausts its remaining liquidity.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.